Molecular target class is predictive of in vitro response profile

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Preclinical cellular response profiling is crucial for developing new cancer therapeutics.
• Predicting clinical efficacy using in vitro tumor models helps identify responsive tumors.
• Understanding drug response patterns across diverse cell lines reveals the value of molecular target classes.

Purpose of the Study:

• To evaluate the efficacy of 19 compounds against 311 cancer cell lines.
• To determine if molecular target class influences drug response in specific tumor types.
• To investigate the role of cellular phenotypes in drug response profiles.

Main Methods:

• A diverse panel of 311 cancer cell lines was treated with 19 different compounds.
• Cellular proliferation responses were measured to assess drug efficacy.
• Data were analyzed to correlate molecular target class and tumor histology with drug response.

Main Results:

• Phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, insulin-like growth factor-I receptor (IGF-IR), and mitotic inhibitors showed target class-specific responses.
• PI3K/AKT/mTOR inhibitors were more effective in breast cancer cell lines.
• IGF-IR inhibitors selectively inhibited colon cancer cell lines.
• Luminal breast cancer cells exhibited distinct response profiles compared to basal cells.

Conclusions:

• Molecular target class is a key determinant of drug response in cancer cell lines.
• Drug response is influenced by tumor histology and specific cellular phenotypes.
• This study supports a rational clinical approach for patient stratification based on molecular targets and tumor characteristics.